Related Experiment Videos
Psoriasiform eruption induced by infliximab
María M Verea1, Jesús Del Pozo, M Teresa Yebra-Pimentel
1Department of Dermatology, Hospital Juan Canalejo, La Coruña, Spain. der@canalejo.org
The Annals of Pharmacotherapy
|January 27, 2004
Summary
Infliximab, a Crohn's disease medication, can cause a psoriasiform eruption. This first-time report details a patient who developed this skin reaction, which resolved after stopping the drug.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Infliximab is a monoclonal antibody targeting tumor necrosis factor-alfa, used for conditions like Crohn's disease.
- Various cutaneous reactions have been linked to infliximab therapy.
- Psoriasiform dermatitis is a known drug side effect but not previously reported with infliximab.
Observation:
- A 46-year-old woman with Crohn's disease developed itchy, red, scaling plaques on her extremities and buttocks.
- These lesions appeared after receiving intravenous infliximab infusions.
- Histopathology revealed a lichenoid pattern.
Findings:
- The patient's skin lesions resolved after discontinuing infliximab.
- A causality assessment indicated a probable link between infliximab and the psoriasiform eruption.
- This case presents a unique clinico-pathologic dissociation, with lichenoid dermatitis histopathology.
Implications:
- This case expands the known spectrum of cutaneous adverse events associated with infliximab.
- It highlights the importance of considering infliximab as a potential cause of psoriasiform dermatitis.
- Further investigation into the mechanisms of infliximab-induced skin reactions may be warranted.